Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

Equality Impact Assessment (Guidance development) (PDF 155 KB)

Register of interests (PDF 146 KB)

Final draft guidance

Final appraisal document (PDF 244 KB)

Committee papers - ACM2 (PDF 1.31 MB)

Public committee slides - ACM2 (PDF 1.09 MB)

Draft guidance

Appraisal consultation document (online commenting)

Appraisal consultation document (PDF version) (PDF 262 KB)

Committee papers - ACM1 (PDF 4.7 MB)

Public committee slides - ACM1 (PDF 1.46 MB)

Final scope (PDF 189 KB)

Final stakeholder list (PDF 213 KB)

Final appraisal document - TA579 (PDF 257 KB)

Committee papers - TA579 (PDF 13.04 MB)

Public committee slides - TA579 (PDF 9.28 MB)

Final appraisal document - managed access agreement - TA579 (PDF 372 KB)

Equality impact assessment - TA579 (PDF 142 KB)

Register of interests - TA579 (PDF 159 KB)

Final scope - TA579 (PDF 245 KB)

Final stakeholder list - TA579 (PDF 347 KB)

NICE's response to comments on the draft scope and provisional stakeholder list - TA579 (PDF 263 KB)

Equality impact assessment (Scoping) - TA579 (PDF 176 KB)